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„Alles Wissen und alle Vermehrung unseres Wissens endet nicht mit einem Schlusspunkt, 
sondern mit Fragezeichen.“ 
 
“All knowledge and all increase of our knowledge do not culminate in an end; instead there 
will be more questions.” 
 
Hermann Hesse 
  

  
ABSTRACT 
Autoimmune diseases are complex multifactorial diseases, and their pathogenesis is only 
partially understood, but both genetic, as well as environmental factors, have been correlated 
to an increased risk for the diseases. Genome-wide association studies of Sjögren’s syndrome, 
systemic lupus erythematosus, and rheumatoid arthritis have identified many risk loci; most 
studies include associations to the FAM167A-BLK locus. A significantly increased expression 
of FAM167A in cells carrying disease-associated alleles was shown by expression quantitative 
trait loci analyses in peripheral blood cells. This finding makes FAM167A a candidate gene for 
disease susceptibility. However, the function of FAM167A and the only homologous protein, 
its gene family member, FAM167B, was unknown when this thesis was initiated.  
This thesis aims to elucidate the function of the FAM167 genes and their role in the 
pathogenesis of systemic autoimmune diseases. Immunohistochemistry staining of the 
autoimmune target organ, salivary glands of patients with Sjögren’s syndrome, revealed 
expression of FAM167A in cells both in the inflammatory foci and interstitium. Most were 
confirmed as B cells, including plasma cells, by double staining. Further, the degree of the 
FAM167A staining correlated with the focus score, IgG levels, and autoantibodies present in 
the patients. Investigating the FAM167 genes and the encoded proteins with bioinformatic 
methods revealed that they are highly conserved in vertebrates, contain no known protein 
motifs but a high content of disordered secondary structures. Based on this observation the 
encoded proteins were denoted disordered autoimmunity (DIORA) -1 and -2. The proteins 
both localize to the cytosol but are found in distinct immune cell subsets and different organs. 
To investigate their function at the whole organism level, we established two knock-out 
mouse strains. Both Fam167a and Fam167b deficient mice were viable - but Fam167a 
deficient mice showed lower body weight, increased kidney weight, and proteinuria in older 
animals. Further, alterations in serum immunoglobulins and B cell populations were detected 
together with an expanded B1a cell population, which exhibited signs of metabolic activation 
at the transcriptomic level. Contrarily, Fam167b deficient mice demonstrated no gross 
malformations. However, their microglia displayed altered expression of genes belonging to 
pathways regulated by interferon as well as pathways of chemotaxis, cell adhesion, migration, 
and inflammatory responses. Based on proximity labeling experiments and annotated 
protein-protein interactions, we suggest that DIORA-1 and DIORA-2 share MRCKA and 
MRCKB, both regulators of the cytoskeleton, as interaction partners.  
In summary, this thesis presents the initial characterization of two genes with unknown 
function. Based on the findings, we speculate that the FAM167 genes contribute to immune 
function including antibody isotype determination and immunoglobulin production. 
However, further studies are needed to explore the molecular activity of FAM167A and 
FAM167B in more detail. In the future, a detailed understanding of the pathways involved in 
autoimmune pathogenesis such as Sjögren’s syndrome, lupus, or rheumatoid arthritis might 
result in the development of novel therapeutics for the benefit of the patients.   
POPULÄRVETENSKAPLIG SAMMANFATTNING 
Ett välfungerande immunförsvar skyddar oss från sjukdom, framför allt från infektioner och 
skadliga ämnen. Om immunförsvaret inte fungerar som det ska kan det bilda antikroppar 
mot den egna kroppen. Dessa sjukliga processer kan i slutändan leda till kroniska 
inflammationer och skada frisk vävnad. Till exempel har patienter med Sjögrens syndrom 
problem med muntorrhet och torra ögon i och med att immunförsvaret förstör saliv- och 
tårkörtlarna. Utöver körtelproblem kan inre organ och det centrala nervsystemet drabbas av 
inflammationer. Många patienter med Sjögrens syndrom lider av trötthet, depressioner, led- 
och muskelvärk samt en förhöjd risk för utveckling av cancerformen lymfom. Generellt 
begränsas livskvalitén hos patienter med Sjögrens syndrom. De har även ofta en kortare 
medellivslängd. För närvarande går sjukdomen tyvärr inte att bota. Symptomen går dock att 
lindra. Därför vill vi med vår forskning uppnå en bättre förståelse av sjukdomen. Genom det 
hoppas vi att kunna bidra till utvecklingen av nya behandlingsmetoder.  
Sjögrens syndrom är en komplex bindvävssjukdom där orsaken till sjukdomsutveckling inte 
är känd i sin helhet. Vi vet dock att både arvsanlag och miljöfaktorer ökar risken. I studier 
med många både friska och sjuka deltagare har man kunnat visa på många små variationer i 
arvsanlagen som ökar risken för sjukdomens utbrott. En av dessa variationer befinner sig 
mellan arvsanlagen FAM167A och BLK. Denna variation ökar produktionen av FAM167A. 
FAM167A produceras bland annat av immunceller som har en viktig roll i utvecklingen av 
sjukdomen. Utifrån detta kan vi dra slutsatsen att arvsanlagen FAM167A predisponerar för 
Sjögrens syndrom och eventuellt också andra bindvävssjukdomar. När denna avhandling 
påbörjades var funktionerna för de båda arvsanlagen FAM167A och det besläktade FAM167B 
helt okända.  
Målet med avhandlingen har varit att kartlägga båda arvsanlagens funktioner och deras 
bidrag till sjukdomsutvecklingen.  
Till en början har vi undersökt i vilken utsträckning arvsanlagen förkommer i salivkörtlarna 
hos patienter med Sjögrens syndrom. Det hittades stora mängder av proteinet FAM167A i 
immunceller som invaderar salivkörtlarna, inklusive i de immunceller som producerar 
antikroppar. Dessutom fann vi ett samband mellan mängden FAM167A i salivkörtlarna och 
antalet invaderande immunceller samt en ökad mängd antikroppar och förekomst av 
autoantikroppar i blodet.  
För att dra slutsatser om betydelsen av de två FAM167 arvsanlagen för en hel organism har vi 
modifierat arvsanlagen hos möss så att de saknar den ena eller andra av anlaget. Möss utan 
  
FAM167A är livsdugliga men får med tilltagande ålder en lägre vikt och uppvisar 
dysfunktioner av njurarna. Möss utan FAM167A uppvisar även förändringar vad gäller 
antikroppsklasser och delpopulationer av immunceller. Hos möss som saknar FAM167B 
finns generellt färre förändringar. Vi fann dock förändringar av mikroglia, som är en typ av 
immuncell i hjärnan.  
För att förstå den cellulära funktionen av FAM167B har vi identifierat proteiner som 
interagerar med FAM167B protein i cellen. Bland annat har vi funnit att proteinerna MRCKA 
och MRCKB är interaktionspartners. Båda dessa protein reglerar cellrörelser.  
För första gången presenterar vi här en beskrivning av de två FAM167 arvsanlagens funktion 
som tidigare har varit okänd. Våra resultat antyder att de har en roll i olika processer såsom 
cellrörelse och immunfunktion, med särskild betydelse för produktion av antikroppar. Fler 
studier behövs för att få en mer detaljerad bild av arvsanlagen funktion och deras bidrag till 
utvecklingen av Sjögrens syndrom. I framtiden kan en bättre förståelse för arvsanlagens 
funktion möjliggöra utveckling av nya behandlingar för patienter med Sjögrens syndrom och 
andra inflammatoriska sjukdomar.  
 
  
POPULÄRWISSENSCHAFTLICHE ZUSAMMENFASSUNG 
Ein gut funktionierendes Immunsystem beschützt uns vor Krankheit, insbesondere hilft es 
bei der Abwehr von Infektionen und anderen Schadstoffen. Funktioniert das Immunsystem 
aber nicht wie es soll, kann dieses zu der Produktion von Autoantikörpern gegen den eigenen 
Körper führen. Dieser krankhafte Prozess kann schlussendlich die Zerstörung von gesundem 
Gewebe und eine chronische Entzündung verursachen. Zum Beispiel leiden Patienten mit 
Sjögren-Syndrom an Mundtrockenheit und trockenen Augen, da das Immunsystem die 
Speichel- und Tränendrüsen stark schädigt. Zusätzlich zu der Schädigung der Drüsen kann es 
zu weiteren entzündlichen Veränderungen in inneren Organen und im zentralen 
Nervensystem kommen. Viele Patienten mit Sjögren-Syndrom sind zudem von 
Gelenkschmerzen, Muskelschmerzen, Müdigkeit, Depressionen und einem erhöhten Risiko 
für die Krebsform Lymphom betroffen. Im Allgemeinen ist die Lebensqualität für die meisten 
Patienten mit Sjögren-Syndrom stark beeinträchtigt und deren Lebenserwartung häufig 
verkürzt. Derzeit gibt es leider keine heilende Behandlung für die betroffenen Patienten, 
stattdessen können lediglich deren Symptome gelindert werden. Deshalb beabsichtigen wir 
mit unserer Forschung zum grundlegenden Verständnis der Krankheitsentstehung 
beizutragen, sodass in Zukunft die Entwicklung von neuartigen Therapien möglich ist.  
Das Sjögren-Syndrom ist eine komplexe rheumatische Erkrankung und die Ursachen für 
dessen Entstehung sind im Detail nicht verstanden. Wir wissen jedoch, dass sowohl 
schädliche Umwelteinflüsse als auch Vererbung zur Krankheitsentstehung beitragen. Studien 
- an denen sowohl erkrankte als auch gesunde Menschen teilgenommen haben - entdeckten 
viele kleine Variationen in den Erbanlagen, die ein erhöhtes Risiko für das Entstehen von 
rheumatischen Erkrankungen verursachen. Eine dieser Variationen liegt zwischen den 
Erbanlagen FAM167A und BLK. Diese Variation steigert die Produktion von FAM167A. 
Darüber hinaus wird FAM167A unter anderem in Immunzellen produziert, die eine 
Hauptrolle bei der Krankheitsentstehung spielen. Auf der Grundlage dieser Befunde 
schlussfolgern wir, dass die FAM167A Erbanlage zur Prädisposition von rheumatischen 
Erkrankungen beiträgt. Als diese Doktorarbeit begonnen wurde, waren die Funktionen von 
FAM167A und deren einzigen verwandten Erbanlage, FAM167B, komplett unbekannt.  
Ziel dieser Arbeit ist, die Funktion der beiden FAM167 Erbanlagen und deren Beitrag zur 
Krankheitsentstehung des Sjögren-Syndroms zu untersuchen.  
Als erstes haben wir untersucht, in welchem Umfang das Protein FAM167A in den 
entzündeten Speicheldrüsen von Patienten mit Sjögren-Syndrom vorkommt. Hohe Mengen 
des FAM167A Proteins wurden in Immunzellen, die an dem krankhaften Eindringen in die 
  
Speicheldrüsen beteiligt sind und solchen, die Antikörper produzieren, gefunden. Außerdem 
konnten wir einen Zusammenhang zwischen der FAM167A Menge und der Anzahl der in 
die Drüse eindringenden Immunzellen sowie mit der Erhöhung von Antikörpern als auch 
mit dem Vorkommen von Autoantikörpern im Blut herstellen. 
Um die Bedeutung der beiden FAM167 Erbanlagen für den ganzen Organismus zu verstehen, 
haben wir die Erbanlagen von Mäusen so verändert, dass ihnen jeweils eine der beiden fehlt. 
Mäuse, die kein FAM167A produzieren sind lebensfähig, bekommen jedoch mit 
zunehmendem Alter ein geringeres Gewicht und zeigen Funktionsminderungen der Nieren. 
Auch zeigen diese Mäuse abweichende Mengen innerhalb der verschiedenen 
Antikörperklassen und in einigen Teilpopulationen von Immunzellen. Bei Mäusen ohne die 
FAM167B Erbanlage sind die Veränderungen generell deutlich weniger, jedoch gibt es 
Veränderungen in den Mikroglia, einer Sorte von Immunzellen des Gehirns.  
Um die Funktion von FAM167B Proteinen innerhalb der Zelle zu verstehen, haben wir 
interagierende Proteine identifiziert. Unter anderem haben wir MRCKA und MRCKB als 
Interaktionspartner feststellen können. Diese beiden Proteine sind Regulatoren von 
Zellbewegungen.  
In dieser Arbeit wird zum ersten Mal eine Beschreibung der zwei FAM167 Erbanlagen, deren 
Funktion unbekannt war, vorgelegt. Unsere Resultate lassen vermuten, dass die FAM167 
Erbanlagen eine Rolle in Prozessen wie Zellbewegung und Immunfunktion, insbesondere der 
Produktion von Antikörpern, spielen. Weitere Untersuchungen sind nötig, um ein 
detaillierteres Bild von der Funktion beider Erbanlagen und deren Beitrag zur 
Krankheitsentstehung des Sjögren-Syndroms zu erhalten. In Zukunft wird das bessere 
Verständnis der für die Krankheitsentstehung verantwortlichen Gene die Entwicklung neuer 
Therapien für Patienten mit Sjögren-Syndrom und anderen rheumatischen Erkrankungen 
ermöglichen. 
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1 INTRODUCTION 
 
Autoimmune diseases impose a lifelong burden on the affected patients. Even though our 
understanding of these complex diseases has expanded, we still do not fully comprehend 
the disease pathogenesis. Elucidating the molecular pathways behind disease onset and 
progression will allow us to develop more specific therapies to alleviate the patients’ 
symptoms and to potentially constrain and cure the disease.  
 
1.1 A brief overview of the immune system 
The primary task of the immune system is to maintain homeostasis in the organism by 
clearing pathogens, tumor cells, and dying cells. These functions are executed by a broad 
spectrum of molecules, cells, and tissues.  
The immune system can be divided into two general arms: the innate and acquired/ 
adaptive immunity. The innate immunity predominately provides a rapid and unspecific 
defense against pathogens. Contrarily, acquired immunity can adapt to novel threats as it 
has the potential to memorize, specify and diversify. Thus, it can develop a more efficient 
immune response than the innate immunity, but the adaptive response usually takes more 
time to develop. However, the memory allows the adaptive immunity to elicit a specific and 
more rapid response to pathogens previously encountered.  
Granulocytes, monocytes, tissue-resident macrophages, and natural killer cells are the 
immune cells contributing to innate immunity. B and T cells also have innate functions but 
are the cells responsible for developing the adaptive immunity. T cells develop in the 
thymus and are responsible for cell-mediated immunity. B cells develop in the bone marrow 
and then migrate to lymphoid tissues where they mediate humoral immunity.  
In the healthy human, all immune processes are well orchestrated holding infections at bay. 
Dysregulation within the immune system may result in immunodeficiency, allergies/ 
hypersensitivity, inflammatory/autoimmune diseases, or cancer.  
 
 2 
1.2 Autoimmune diseases 
Autoimmune diseases (AID) develop in individuals with uncontrolled immune responses 
to self-antigens. Between 2 to 5 % of the population in the developed world suffer from this 
family of disorders [1-3]. A majority of these are rheumatic diseases, in which the chronic 
inflammatory process leads to tissue destruction resulting in increased morbidity and for 
most of these conditions, a shorter life expectancy. The onset and progression of 
autoimmune diseases may be explained by genetic predisposition, environmental factors, 
and immune regulation [4]. As no curative treatment is available yet, there is a critical need 
for a deeper understanding of the processes behind chronic autoimmune inflammation.  
The current paradigm on AID pathogenesis is that disease may be initiated after 
environmental triggering in genetically susceptible individuals [5]. The evidence for genetic 
predisposition stems from studies showing familiar clustering as well as the elevated 
concordance rate in monozygotic twins [6, 7]. Additionally, many genome-wide association 
studies (GWAS) have deepened our understanding of the genetic risk contributing to AID. 
This is discussed in more detail below. Many different environmental triggers have been 
associated with autoimmunity, in particular, infections, toxic chemicals, dietary 
components, microbiota and endogenous retro-elements [8-11]. Notably, genes and 
environment also interact at the level of epigenetics, and several epigenetic modifications 
have been shown to influence the development and progression of AID [12-14]. 
How the immune dysregulation causes to break tolerance at the cellular and molecular level 
may be explained in different ways. B and T cell development is tightly regulated to avoid 
auto-reactivity, highly self-reactive cells are already deleted centrally, whereas only 
moderately self-reactive cells are kept in check by immune cells responsible for peripheral 
tolerance. However, if autoreactive cells escape these checkpoints, they may cause the onset 
of disease in genetically predisposed individuals [15, 16]. Paradoxically, many autoantigens 
are intracellular and should thus be hidden or inhibited from binding to antibodies in the 
extracellular spaces. However, autoantibodies against peptides derived from intracellular 
proteins are present in many autoimmune patients. Three different processes have been 
suggested to cause autoantibodies to bind intracellular antigens: apoptosis, antigen 
modification, and cross-reactivity [17]. More specifically, infections with extensive tissue 
damage may cause a mechanism called bystander activation where both increased levels of 
strong pro-inflammatory signals, as well as self-antigens, are present extracellularly, 
allowing the activation of autoreactive cells [18]. During the process of molecular mimicry, 
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initially pathogen-derived peptides may resemble self-antigens and activate autoreactive 
immune cells, which target the host tissue after the original infection is cleared [19]. 
Additionally, both smoking and bacterial infections have been shown to modify epitopes 
through post-translational modifications and subsequently may facilitate autoimmunity 
[20, 21]. Furthermore, the same modification may be recognized on other antigens, 
resulting in epitope spreading and autoimmunity to more self-antigens [22].  
Taken together, aberrant innate, as well as B and T cell responses, together with the 
production of autoantibodies and pro-inflammatory cytokines, may give rise to 
autoimmunity. Hence, many immune pathways contribute to autoimmunity including IFN, 
TLR, and ROS signaling. It may be noteworthy, that several of the pathways involved have 
also been identified in genetic association studies. The present project was developed to 
obtain an understanding of the function of a novel gene the research group had identified as 
associated with Sjögren’s syndrome [23]. 
 
1.3 Sjögren’s syndrome 
Primary Sjögren’s syndrome (pSS) is a chronic autoimmune rheumatic disease with a 
prevalence of 0.1 - 0.3 %, affecting women almost twenty times more often than men [24]. 
The most common symptom is dryness of mouth and eyes, caused by the dysfunction of 
exocrine glands. Together with manifestations such as fatigue, arthralgia, and increased risk 
of developing lymphoma, the disease severely impacts the lives of the patients. Anti-Ro/SSA 
and anti-La/SSB autoantibodies are present in approximately 70 % of patients, and together 
with histological evidence of inflammation in the salivary glands are used in addition to the 
clinical symptoms to establish the diagnosis [25].  
At the organ level, Sjögren’s syndrome is characterized by infiltrates of lymphocytes into 
exocrine glands, especially into the lacrimal and salivary glands. The infiltration is often 
accompanied by the production of inflammatory cytokines and autoantibodies by activated 
B cells [26]. The lymphocytic infiltrates result in reduced or loss of secretory function of the 
glands, resulting in the cardinal symptoms dry eyes and dry mouth. Beyond this, extra-
glandular manifestations such as interstitial pulmonary disease, vasculitis, and thyroid 
disease are also observed in patients with pSS. Additionally, the incidence rate for 
lymphomas is increased 15 fold [27]. Serological screenings have revealed that IgM is 
usually decreased while IgA is increased and IgG highly elevated in patients with pSS. It has 
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also been shown that the peripheral blood of patients with pSS includes a higher percentage 
of specific subclasses of activated B cells [28], decreased levels of memory B cells [29], and 
CXCR5+ cells [30].  
Minor salivary gland biopsies are commonly taken during the diagnosis procedure. The 
focus score is a diagnostic criterion and represents the number of mononuclear cell 
infiltrates containing at least 50 inflammatory cells in a 4 mm2 big section of the gland. 
Several features have been attributed to the B cells in the glandular infiltrates. Ro and La 
autoantibody-producing cells are found within the salivary gland of patients with pSS [31]. 
Plasma cells in the foci share characteristics with the long-lived plasma cell subtype [32]. An 
increase of CXCR4+CXCR5+ memory B cells within the gland has been confirmed [33].  
The etiology of the disease is not fully understood, but as for other rheumatic diseases, it is 
believed that environmental factors may trigger the disease to develop in genetically 
susceptible individuals [9]. Based on the different incidence rates in female versus male 
patients, direct effects due to the sex chromosomes or indirect effects mediated by sex 
hormones are suspected to play a role in the onset of the disease. One study suggests a role 
of the X chromosome in the susceptibility to autoimmune disease as men with the 
Klinefelter syndrome (47, XXY) are more prevalent among male SLE patients [34]. The sex 
hormone estrogen has been shown to promote an autoimmune phenotype in different mice 
models [35, 36]. To date, no environmental risk factors have been identified for pSS, but 
several gene loci have been associated with the disease. A recent GWAS study demonstrated 
the association to the HLA, IRF5-TNPO3, STAT4, IL12A, FAM167A-BLK, DDX6-CXCR5 
and TNIP1 loci at a genome-wide significant level [23]. Previous genetic studies suggested 
HLA, STAT4, IRF5-TNOP3, EBF1, FAM167A-BLK, STAT4 and TNFSF4 as associated genes 
[37-41].  
The association to the HLA genes is the strongest identified so far for all rheumatic diseases. 
The HLA region is one of the most polymorphic regions in the human genome and 
contains several genes that have been suggested to be involved in disease pathogenesis. The 
HLA proteins are critical molecules in the adaptive immune response. However, the 
molecular mechanism behind the association of different HLA alleles with a wide range of 
immunological disorders is not fully understood [42, 43]. In summary, many genetic 
studies of autoimmune diseases have discovered associations to genes relevant in immune 
processes.  
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1.4 The FAM167A-BLK locus in autoimmune disease 
Among the non-HLA loci that have been repeatedly associated with rheumatic diseases is 
the FAM167A-BLK locus. However, the molecular cause behind this association is not 
understood. Most of the disease-associated SNPs in the FAM167A-BLK locus fall into the 
intergenic region between the two genes, and most of them are positioned closer to the BLK 
gene although the association signal stretches over both genes [23]. Initially, BLK has been 
considered as the cause for the association based on its known role in B cells. 
BLK encodes a tyrosine kinase of the Src family, which contributes to B-cell development, 
differentiation, and signaling [44]. The autoimmunity-associated BLK haplotype has been 
shown to result in altered mRNA and protein expression of BLK in naïve B-cell subsets 
[45]. Alterations in BCR and NFκB signaling for different SNPs in the BLK region have 
been reported to support the hypothesis that the BLK gene is the causal factor behind this 
association [46]. However, rather surprisingly, Blk knock-out mice show no overt immune 
phenotype [47]. Only in Blk-/-Fyn-/-Lyn-/- triple knockout mice an altered B cell development 
has been observed, indicating that these Src kinases can compensate each other’s function 
[48]. On the other hand, FAM167A (family with sequence similarity 167, member A) is 
expressed in a broad range of cells and tissues according to the human protein atlas 
(https://www.proteinatlas.org), but its function remains elusive.  
Moreover, the genetic association to the FAM167A-BLK locus has not only been published 
for pSS [23, 38] but has been shown for several autoimmune diseases (Figure 1). For 
systemic lupus erythematosus (SLE), Hom and colleagues [49], were the first to report the 
association at the genome-wide level, followed by others [50-54]. The association to the 
BLK-FAM167 locus has also been shown in several studies involving rheumatoid arthritis 
(RA) patients [55-57]. Kawasaki disease is an acute vasculitis primarily affecting children. 
The strongest association found in a GWAS of Kawasaki disease by Onouchi et al. [58] is 
the rs2254546 SNP in the FAM167A-BLK region. This association has also been confirmed 
below genome-wide significance level in other studies [59, 60]. Interestingly, the signal from 
the FAM167A-BLK locus is higher than that from the HLA locus in Kawasaki disease. For 
other traits, the association with SNPs in the FAM167A-BLK locus has been shown below 
genome-wide significant level for instance in polymyositis/dermatomyositis [61], systemic 
sclerosis [46, 62, 63], antiphospholipid syndrome [64], and IL-6 cytokine production in 
response to vaccination [65]. However, for giant cell arteritis, an association could not be 
confirmed in a study genotyping two of the representative SNPs in the region, but one allele 
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of a risk SNP could be correlated to an increased incidence of severe ischemic complication 
[66]. Besides the association with autoimmune and rheumatic diseases, two case-control 
studies in Chinese patients with asthma or allergic rhinitis show an association to the 
FAM167A-BLK locus [67, 68]. Further, a bigger genomic fragment, which includes among 
others also the FAM167A-BLK locus, has been associated with keratolytic winter erythema 
[69]. Overall, most of the disease-associated SNPs fall into a small distinct area around SNP 
rs2736240. More specifically, a meta-analysis of that specific SNP rs2736240 also concludes 
that this locus associates to various autoimmune diseases [70]. In most of the studies of pSS, 
SLE and RA the odds ratio for the FAM167A-BLK locus was determined around 1.3. In the 
Kawasaki study by Onouchi et al the mean of the odds ratio is somewhat higher for this 
condition at 1.8 [58].  
Further, the 8p23.1 deletion syndrome that compromises a loss of a 2.4 Mb region 
including several genes in addition to FAM167A is associated with conotruncal heart 
defects, microcephaly and global developmental delay [71]. 8p23.1 also represents one of 
the most extensive known inversions, a common polymorphism, and the association to the 
risk allele in the FAM167A-BLK locus persists independently of the inversion haplotype in 
SLE patients, however, the non-inversion haplotype is associated with SLE and might 
additively affect the pathogenesis of SLE [72].  
Interestingly, cis-eQTL analysis shows a highly increased expression of FAM167A for the 
genotype associated with pSS [23]. Notably, the effect on BLK expression is moderate/low. 
Similar effects were also shown for SLE-associated polymorphisms were the disease-
associated genotype resulted in substantially elevated mRNA expression of FAM167A and 
somewhat increased expression of BLK in transformed cell lines [49]. In line with these 
findings, a recent study found a powerful eQTL effect on FAM167A expression in B cells of 
RA patients [73]. 
 
1.5 The FAM167 gene family  
The genes of the family with sequence similarity 167 (FAM167) are grouped by their 
sequence resemblance. We found that the FAM167 gene family consists of two members, 
FAM167A and FAM167B. Neither of them shows homology to any other annotated genes 
nor encodes any previously known protein domains or motifs. FAM167A is located on 
chromosome 8p23.1. Based on its genetic position the FAM167A gene is also denoted as 
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C8orf13. The gene compromises four exons and encodes a protein of 214 amino acids. The 
FAM167B gene is located on chromosome 1p35.1 and therefore also annotated as C1orf90. 
FAM167B contains two exons encoding for a smaller protein of 163 amino acids. Initially, 
the FAM167 genes were denoted as SEC based on their partial similarity to the sequence of 
an oncogene from a breast cancer cell line published 1990 [74]. However, no such gene is 
currently annotated in the NCBI database. FAM167A was mapped and sequenced for the 
first time in a study on the keratolytic winter erythema locus [69], which also included the 
previously cloned human BLK [75].  
 
1.5.1 FAM167A  
When this thesis was initiated, there were no publications directly addressing FAM167A 
expression, localization, or function. However, there were several reports on genetic disease 
associations within the region.  
FAM167A is transcribed in many cell lines and tissues. Interestingly, the SNPs within the 
FAM167A-BLK region that are associated with pSS and SLE locate to the same region 
targeted by epigenetic modifications in B cells, indicating that expression differences may 
indeed relate to immune cells and the disease [76, 77]. FAM167A is also one of several genes 
that are hypo-methylated and upregulated in pilocytic astrocytomas compared to diffuse 
astrocytomas [78]. Another association with cancer comes from FAM167A being 
positioned within one of the 47 putative long-range epigenetic silencing regions in prostate 
cancer [79]. CNV (copy number variation) was also found within FAM167A-AS1 (C8orf12) 
in patients with disorders of sexual development [80]. FAM167A is also one of the early 
genes expressed in the ventricular zone in brains of ferrets [81], and in a co-culture of bone 
marrow stromal cells of healthy donors with the myeloid leukemia cell line K562, FAM167A 
was in the top ten of upregulated genes [82]. Furthermore, FAM167A was one of four genes 
to be associated with telomerase length throughout aging [83]. All these findings are rather 
vague, therefore only a more targeted approach will help to elucidate the function of 
FAM167A.  
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1.5.2 FAM167B  
FAM167B is the other member of this gene family. Its functional role was not understood 
when this project was launched. High transcription of FAM167B has been reported in 
publically available databases in melanoma cell lines (cancer cell line encyclopedia, 
https://portals.broadinstitute.org/ccle) and for adrenal, kidney and thyroid tissue (GTEx, 
https://gtexportal.org/). Generally, the FAM167B gene and protein are scarcely covered in 
the scientific literature. Interestingly, one study characterizing the pre-integration 
complexes of HIV (human immunodeficiency virus) within infected cells found FAM167B 
is one of the top ten proteins unique to the infected samples [84]. Thus, one could speculate 
that FAM167B is a host factor directly or indirectly involved in HIV replication. 
Additionally, FAM167B was also found to be one of 72 host factors required for VSV 
infection through a big siRNA screen [85]. Going hand in hand with the finding of high 
FAM167B transcription in melanoma cell lines, two independent studies show increased 
FAM167B transcription in melanoma and both studies are indicating an association to 
more aggressive tumors [86, 87]. Fam167b was observed to be one of 50 up- and 
downregulated genes in pancreatic islets of Ffar3-/- mice that lack the free fatty acid receptor-
3 gene [88]. FAM167B has also been found as one of many genes upregulated upon IL-6 
and IL-6 trans-signaling in human airway smooth muscle cells [89]. Fam167b was one of 
the genes characterized by the ingenuity pathway analysis associating a network of genes 
involved in inflammatory processes with the overexpression of miR-30b in the mouse 
mammary gland [90]. Fam167b is also one of 1100 genes differently regulated in bone 
marrow-derived small embryonic-like pluripotent stem cells exposed to intermittent 
hypoxia [91]. FAM167B potentially, together with its neighboring genes, forms a risk locus 
for the eating disorder anorexia nervosa (p=9.6 x 10-6) [92]. All these findings are rather 
indicative but might be used to from working hypotheses while exploring the biological 
function of FAM167B.  
  9 
 
 
Figure 1: Genetic studies showing an association to the FAM167-BLK locus are denoted 
with the position of the most significant SNP and their respective p-value, the label further 
includes the relevant disease or trait and the first author of the study.  
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2 AIM 
 
Genetic association studies in pSS, SLE, RA, and Kawasaki disease have demonstrated that 
individuals with specific polymorphisms in the FAM167A-BLK locus are more prone to 
develop these diseases. eQTL analyses have shown moderate effects of associated 
polymorphisms concerning the expression of BLK, while the genotype has a significant 
impact on the expression of FAM167A. BLK (B lymphocyte kinase) has been identified as 
acting downstream of the B cell receptor, while no function has yet been assigned to 
FAM167A. This thesis project aims to characterize the FAM167 gene family and to gain a 
detailed understanding of the two gene family members, FAM167A and FAM167B. 
Specifically, the project entails: 
 
- Gathering and interpreting information on the FAM167 family genes and translated 
products from public databases to understand their evolution, conservation, expression, 
and protein features (Paper I) 
 
- Defining organ and cellular expression of FAM167A and FAM167B in different organs 
and cells (human and mouse) (Paper I and II) 
 
- Test for FAM167A expression in autoimmune target organs, understand staining pattern 
and correlate with clinical parameters of the patients (Paper II) 
 
- Generation of Fam167a and Fam167b knock-out mice to understand the importance and 
function of the genes (Paper III and IV) 
 
- Identify interaction partners of the FAM167B protein to further understand its role 
within the cell (Paper IV) 
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3 METHODOLOGICAL CONSIDERATIONS 
 
The experimental methods which are central to the findings presented in this thesis are 
discussed with a focus on advantages and limitations in this section. The detailed description 
of the methods used is available in the respective papers attached.  
 
Localization study with transfected YFP-fusion protein  
Localization experiments were performed by tagging our proteins of interest with another 
fluorescent protein. The fluorescent fusion protein can be easily detected in the microscope 
and marks the localization of the protein of interest. The main advantage of this approach is 
that it only requires the cloning of the fusion protein, all other reagents are commercially 
available. Furthermore, the expression construct is delivered by transfection, which can be 
directly implemented in a wide range of cell lines. Unfortunately, the transfection usually 
results in high expression and may induce artifacts or aggregates. Besides, every genetic 
modification, here the tagging, may cause alterations to the protein, both in function or 
localization as the tag may conceal or block relevant protein structures. In sum, this kind of 
localization study is easily implemented but should be complemented by an alternative 
approach to prove the biological relevance of the findings. 
 
Immunohistochemistry 
This method detects the distribution of specific antigens in tissue sections or cell suspensions 
on microscope slides. The detection is mediated by antibodies specific for the target of 
interest. Next, the staining can be visualized by established secondary antibodies detecting the 
constant domain and which are coupled to a fluorescent dye or an enzyme catalyzing a 
colorimetric reaction. Therefore, this method is strictly dependent on the availability of 
specific antibodies. Often the use of monoclonal antibodies is preferred as they recognize only 
one epitope. Different experimental conditions may change the conformation of the epitope, 
and thus the employability of the monoclonal has to be confirmed in each experimental set-
up.  
Currently, there are no monoclonal anti-FAM167A or FAM167B antibodies available. 
However, the human protein atlas consortium has developed several affinity-purified 
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polyclonal antibodies. We tested all commercially available antibodies on cell lysates 
containing overexpressed tagged FAM167 proteins. We found that the HPA030426 anti-
FAM167A antibody exhibited the smallest amount of non specific binding and reliably 
stained its target. Its cross-reactivity to the mouse Fam167a protein was not as strong as to the 
human protein, and therefore we restricted our investigations of FAM167A by 
immunohistochemistry to human tissues and cells. A disadvantage of using polyclonal 
antibodies for immunochemistry may be the lesser specificity resulting in background 
staining, but they may be less sensitive to conformational changes of the epitope as they 
recognize many epitopes. Luckily, our antibody of choice exhibited no detectable background 
staining and enabled us to identify a FAM167A staining pattern discriminating samples from 
patients with pSS versus non-SS. To conclude, immunohistochemistry allows localization and 
expression studies in a broad variety of cells and tissues but is critically dependent on the 
availability and quality of the employed antibodies.  
 
Fam167a knock-out mouse 
To elucidate the unknown function of Fam167a, we generated a knock-out (KO) mouse 
strain. Based on the association to AID and expression in various immune cells we suspected 
a function of Diora-1 in the immune system. The human FAM167A shares high sequence 
similarity with the murine Fam167a as expected for paralogs. The murine immune system 
shares the main features with the human immune system. Therefore, mice became central to 
immunological research: many relevant disease models and tools have been established. 
Furthermore, we chose the classical approach of deleting the gene of interest to understand 
which processes are disturbed in its absence. 
To generate Fam167a deficient mice we employed the by the International Mouse 
Phenotyping Consortium [93] predesigned construct Fam167atm1(KOMP)Vlcg. In this construct, 
the gene is entirely deleted. An inserted LacZ reporter allows longitudinal expression profiling 
of the gene independently from the availability of specific antibodies.  
However, the genomic deletion may alter relevant regulatory sequences or disturb other 
coding sequences in or nearby the modified locus. Due to the complexity of the genome, it 
may be complicated to prove that the observed phenotype is not caused by the deletion of 
other relevant genomic regions. Nevertheless, cellular knock-down experiments which target 
genes post-transcriptionally could be complementary to confirm the function of the gene. 
 
  15 
Fam167b gene trap mouse 
For the generation of FAM167b deficient mice, we used the Fam167btm1a(EUCOMM)Wtsi construct 
also developed by the International Mouse Phenotyping Consortium [93]. This design is 
called ‘KO first allele (reporter-tagged insertion with conditional potential)’. In detail, the 
insertion of additional sequences disrupts the splicing of the two exons and therefore the 
correct expression of the gene. Exon 1 is instead spliced to the LacZ reporter which allows 
expression profiling. This concept is called gene trap and is assumed to abolish the gene 
expression similarly to classical KO mice. However, a leaky expression is theoretically possible 
and it is advised to confirm the absence of gene expression and its product. In our mouse 
strain, we confirmed the lack of Fam167b transcripts as no anti-mouse Fam167b antibody is 
available.  
Additional inserted genomic sequences allow that the gene trap may be reverted through 
breeding with the correct Flip mouse strain. In an additional breeding step with a specific Cre 
mouse, one may obtain mice with deficient expression in selected tissues or cell populations. 
Hence, the name of the construct, first, it resembles a KO but may be developed to a 
conditional mouse strain.  
 
Proximity labeling assay (BioID2) 
A protein method that uncovers proteins in the vicinity of the protein of interest is highly 
relevant as this allows the description of protein complexes. This method has been refined 
recently by the development of a promiscuous biotin ligase of reduced size, named BioID2 
[94, 95]. The ligation of the small biotin molecule to proximal proteins allows the labeling of 
weak or only transient interactions and subsequently these labeled potential interaction 
partners may be easily extracted.  
As discussed before, the genetic modification necessary to generate the fusion protein 
consisting of the BioID2 ligase and the protein of interest may alter the function or 
localization of the protein. Further, the tagged protein may induce steric hindrance. To 
overcome these limitations, alternative cloning strategies may be tested, e.g. adding the tag to 
the other end of the protein, shorten or prolong the linker between tag and protein of interest.  
In our experiments, we chose a cell line that endogenously expresses FAM167B assuming that 
its natural interaction partners should be expressed in the same cell also. To avoid artifacts 
caused by overexpression, we confirmed that the transduction resulted in very low expression 
of the fusion protein. The utilized biotin ligase has slow kinetics. This may result in the 
 16 
labeling of proteins responsible for its biogenesis, transport, or other processes, which are not 
necessarily relevant for its function. Therefore, conducting several experiments or such 
experiments with the potential for quantification of the hits may promote the discovery of 
relevant hits.  
This method has the potential of uncovering protein complexes and therefore elucidating 
functional networks. Ideally, those candidate novel interactions discovered will be confirmed 
by other methods like co-immunoprecipitation, pull-down, or crosslinking. After that other 
molecular protein or protein structure tools can be utilized like targeted mutagenesis to define 
interaction domains, surface plasmon resonance to measure the quality of the interaction, 
and structure determination of the interaction complex.  
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4 RESULTS AND DISCUSSION 
 
4.1 The BLK-FAM167A is a susceptibility locus in autoimmune diseases; 
moreover, eQTL analyses point towards FAM167A as a causal gene in 
disease pathogenesis  
The rheumatic diseases systemic SLE, pSS, and RA are associated with polymorphisms in the 
FAM167A-BLK locus (Paper I, Figure 1). In large GWAS studies of SLE, RA and pSS this 
association is above genome-wide significance and the increased risk results in odds ratios 
between 1.2 - 1.3 [23, 49, 55]. These risk SNPs are in high linkage disequilibrium. Therefore, 
we assume these represent the same genetic signal. In smaller studies of 
polymyositis/dermatomyositis [61], systemic sclerosis [46, 62, 63], antiphospholipid 
syndrome [64], IL-6 cytokine production after vaccination [65] and allergy [67, 68] 
associations to the FAM167A-BLK locus could also be detected, though, at lower significance 
levels. Interestingly, in Kawasaki disease, the genetic association with the FAM167A-BLK 
locus is stronger than with the HLA locus reflected in a high odds ratio of 1.8 [58]. Additional 
studies will be necessary to understand how FAM167A influences the inflammation of blood 
vessels in the affected patients. While a wide array of genetic studies show associations to the 
FAM167A-BLK locus, the causal SNP has not been identified yet. Overall, the FAM167A-BLK 
locus is associated with several immune disorders with substantial evidence to be a 
susceptibility locus in autoimmune and inflammatory diseases.  
Further, we show a strong eQTL effect of the disease-associated polymorphism on the 
transcription of FAM167A in PBMC (Paper I, Figure 1). This effect is even stronger when 
investigating purified B cells [96]. However, we could not detect that the same polymorphism 
affects FAM167A transcription in monocytes. In line with our findings, the previous GWAS 
of pSS also found the same eQTL effect in PBMC [23]. Before, the first SLE GWAS 
investigating an eQTL effect at the FAM167A-BLK locus found an increment in BLK 
transcription, but an even more prominently increased FAM167A transcription related to 
autoimmunity-associated alleles [49]. A recently published analysis of 101 established risk loci 
in RA in both T and B cells determined the strongest eQTL effect in B cells on the 
transcription of FAM167A [73]. This eQTL study also shows an effect on BLK transcription 
in RA patients. However, this effect is rather moderate compared to the significance of allele-
related FAM167A transcription levels in B cells, although the differential allele-specific BLK 
transcription in T cells was highly significant. In summary, we conclude that several studies 
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show a significantly increased FAM167A transcription by the disease-associated alleles of 
specific polymorphism in several rheumatic diseases.  
The disease-associated polymorphisms fall into the intergenic region between FAM167A and 
BLK. As BLK is expressed in B cells, acting downstream of the BCR, it was long considered 
the culprit behind the association. We found a significant eQTL effect on the transcription of 
BLK with lower expression from disease-associated alleles; however, the effect size on 
FAM167A transcription is greater. These findings do not exclude that BLK contributes to 
disease pathogenesis, but based on the increased transcription of FAM167A related to the 
disease-associated alleles we decided that this uncharacterized gene with unknown function 
deserves a more profound analysis to understand its potential contribution to disease 
pathogenesis. 
One, at first sight, conflicting result is that we do not see increased transcription of FAM167A 
in the PBMC of our patient cohort compared to healthy donors (Paper II, Figure 1). However, 
the analysis is not stratified according to genotype, and as for many autoimmune-associated 
genotypes, it is common also among the healthy population. Thus, the effect of the risk SNP 
on FAM167A transcription might be diluted in this small cohort of mixed genotypes at the 
risk locus.  
Furthermore, we detected a variable transcription of FAM167A in B cells of healthy donors, 
dividing them into two almost equally big groups with either low or elevated FAM167A 
transcription. One could speculate that genetic variability within these donors may contribute 
to the variable transcription. In addition to the genotype, also environmental factors or the 
current immune status of the donors may contribute to differences in the FAM167A 
transcription. Therefore, it would be interesting to understand whether FAM167A is a 
marker, being regulated or a regulator of immune function in B cells.  
Besides, it is highly relevant, that the variable FAM167A exp transcription ression is observed 
in B cells, which are important to autoimmunity. These initial data that not only identified a 
genetic association with FAM167A but also intrinsic and potentially extrinsic regulatory 
effects on transcription of FAM167A make it an interesting candidate gene to contribute to 
disease pathogenesis.  
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4.2 DIORA-1 positive cells reside in the foci and interstitial cells within 
salivary glands of patients with pSS; additionally DIORA-1 staining in the 
salivary glands correlates with the clinical features focus score, IgG, and 
Ro/SSA autoantibody levels 
To increase our insight into the role of FAM167A and its gene product, the DIORA-1 protein, 
in autoimmune disease pathogenesis we stained salivary gland biopsies of patients with 
Sjögren’s syndrome for DIORA-1. DIORA-1 positive cells were found both in lymphocytic 
foci and interstitially in the glands. Moreover, the ductal epithelium stained also positively for 
DIORA-1. The same staining of non-SS patients’ salivary glands hardly identifies any cells 
expressing DIORA-1. Further, a correlation between the staining and focus score was 
observed (Paper II, Figure 1). Based on this finding we assume that mainly the infiltrating 
immune cells stain positively for DIORA-1.  
To further characterize the DIORA-1 positive cells we performed double staining with CD20, 
CD38, and CD138. A majority of the DIORA-1 positive cells were determined as B cells. Also, 
a fraction of the DIORA-1 positive cells was identified as plasma cells. This finding is 
coherent with the transcription of DIORA-1 in B and plasma cells in circulation which was 
confirmed by qPCR. However, plasma cells in circulation are not high expressers of DIORA-1 
whereas DIORA-1 staining is intense in the plasma cells of the inflamed glands of patients 
with pSS. Considering their distinct localization, these plasma cells are not per se comparable 
as they represent two distinct plasma cell subsets and different levels of DIORA-1 expression 
might depend on their further differentiation in the tissue. 
Moreover, the amount of the DIORA-1 staining correlates with the parameters 
hypergammaglobinemia and the presence of Ro/SSA autoantibody in the serum. Based on 
this connection, we speculate that DIORA-1 has a direct impact on antibody levels potentially 
by augmented production or promotion of the IgG class switch. Plasma cells in target organs 
of autoimmunity have been identified to produce autoantibodies [31, 97]. Therefore, future 
experiments might test for the antigen specificity of DIORA-1 positive plasma cells to 
investigate if DIORA-1 expression correlates to the production of autoantibodies.  
In our initial study, DIORA-1 staining did not correlate with patient gender, age, salivary flow 
rate, extraglandular manifestations, or adverse predictors of lymphoma (salivary gland 
enlargement, rheumatoid factor, and lymphopenia). However, to address the potential of 
DIORA-1 staining as a possible novel biomarker or prognostic factor, a larger longitudinal 
study would need to access this in more depth.  
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In summary, these findings suggest that DIORA-1 operates in different B cell subsets and give 
additional indirect evidence for the contribution of DIORA-1 to the inflammatory process.  
 
4.3 The FAM167 gene family is highly conserved in vertebrates and can be 
traced to tunicates, indicating a relevant function in multicellular animals 
We found that homologs to both FAM167A and FAM167B are highly conserved (Paper 1, 
Figure 2). This circumstance does not only allow us to study these genes in classical model 
organisms like mice or zebrafish but also indicates that these genes have a relevant function 
considering that they have not been erased from vertebrate genomes throughout the course of 
millions of years.  
The FAM167 gene family formed before vertebrates developed features of adaptive immunity. 
However, we observed expression in B cells and alterations in the adaptive immune system of 
Fam167a deficient mice. Therefore, we speculate that the gene may have either more than one 
function or an essential function within the cell also affecting pathways that evolved later.  
In the evolutionary tree, tunicates represent animals with a primary innate immune system 
consisting of features like pattern recognition receptors and phagocytic cells. Thus, we 
additionally hypothesize that the genes could have co-evolved with the innate immune 
system, contributing to essential functions within the more complex immune system of 
vertebrates.  
Furthermore, we found that several neighboring genes of both FAM167 genes share high 
homology, suggesting that this genetic fragment was duplicated early during evolution. Gene 
duplication is widespread in more complex genomes and seminal for the diversification of 
function. Hence, the duplication may suggest that the genes within the two loci may have 
acquired different functions through evolution and/or are regulated differently.  
 
4.4 The DIORA protein sequences include no known functional domains and 
are predicted to contain disordered structures 
FAM167A encodes for a protein of 24 kDa and FAM167B for a smaller protein of 18 kDa. At 
the protein sequence level, the domain of unknown function (DUF3259) is annotated at the 
C-terminus of both proteins. This shared domain is the reason for grouping the two genes 
into one family, although high sequence similarity can be observed also at the more 
N-terminal parts of the proteins. No molecular function has been linked to the DUF3259 
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sequence motif. Besides, little is known on the proteins. The sequence is predicted to contain 
no transmembrane or localization sequences. In consequence, they are predicted to localize to 
the cytosol.  
The homology analysis of FAM167 proteins from thoroughly sequenced model organisms 
detected conserved sequence stretches both at the N- and C-terminus with a less conserved 
linker sequence in between (Paper I, Figure 3). Secondary structure predictions reveal a large 
degree of disorder, mainly in the N-terminal part of both proteins. Overall, the pattern of the 
disorder is similar in both proteins (Paper I, Figure 4). However, the C-terminus comprises 
more helical and coil-coiled sequence structures.  
Based on the evidence of an association with autoimmunity and the disordered structure we 
denoted this protein/gene family as “Disordered Autoimmunity” DIORA. Proteins with 
disordered secondary/tertiary structures are loosely grouped as “Intrinsically Disordered 
Proteins” (IDP). A large fraction of eukaryotic proteins contains disordered structural 
elements and especially yet uncharacterized proteins are more frequently disordered 
compared to those already annotated, making it a class of proteins with a high potential for 
discovering novel functions [98]. Many IDPs contribute to intracellular signaling and 
regulatory processes, and many of them function as central interaction hubs within cells. 
Gsponer and Babu classify IDPs according to their functional and structural characteristics 
such as “(i) their facilitated regulation via diverse post-translational modifications of specific 
amino acids (ii) scaffolding and recruitment of different binding partners in space and time 
via the "fly-casting" mechanism, through peptide motifs and by coupling folding with binding 
and (iii) conformational variability and adaptability” [99]. As the DIORA proteins contain 
vast stretches of flexible structure, they possibly execute their function via interaction with 
several proteins and consequently regulate cellular pathways.  
 
4.5 DIORA-1 and DIORA-2 both localize to the cytosol but have distinct 
expression patterns within organs and immune cell subsets 
Next, we investigated the expression pattern of the DIORA proteins. By understanding where 
a protein is present, we obtain an initial understanding of how it operates. Overexpression of 
both DIORA proteins shows a dotted pattern within the cell cytoplasm. Overexpression of 
proteins intracellularly may lead to aggregates and artefactual patterns, but a similar pattern 
was confirmed for DIORA-1 by antibody staining of non-transfected primary 
bronchoalveolar lavage (BAL) cells (Paper I, Figure 5). The pattern resembles the distribution 
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of endosomes; confirmation of the co-localization would, however, require co-staining with 
adequate markers.  
Further, more detailed localization studies on DIORA-2 will require a highly specific 
antibody to be produced. Currently, the human protein atlas annotates DIORA-2 to co-
localize with the actin skeleton. This localization may be explained by our finding that two 
interactors identified below are regulators of the cytoskeleton. However, this is in conflict 
with our overexpression data, but the intracellular pattern might also vary in different cell 
types or fluctuate depending on external signals, activation station, cell division, or other 
factors. The production of specific monoclonal antibodies will be required to refine the 
intracellular expression of the DIORA proteins. In sum, our initial data suggest that both 
DIORA proteins are expressed within the cytosol.  
The highest transcription of Fam167a was observed in the lungs of mice, but it was also 
expressed in many other organs including spleen, skeletal muscle, brain, liver, thymus, lymph 
node, and heart. The high expression in the lung was confirmed in human lung biopsy and 
BAL cells (Paper I, Figure 5). The staining of the reporter gene in the lungs of Fam167a 
deficient mice confirms an epithelial pattern (Paper III, Figure 1). According to the ImmGen 
database (Figure 2, www.immgen.org), Fam167a is transcribed in many immune cells, 
including B and B1a cells. According to the cancer cell line encyclopedia 
(https://portals.broadinstitute.org/ccle), FAM167A is transcribed in a wide variety of cell lines 
and unusually high in the myeloma cell line LP-1 which we also observed (Paper II, 
Figure 1C).  
The lung has been suggested to contribute to the development of AID as exposure to smoke 
or other airborne triggers correlates to an increased incidence rate in RA and SLE. These 
matters are suspected to repetitively activate the immune system through substances in the 
smoke or the increased infection rate and subsequently facilitate the onset of AID. Therefore, 
it would be interesting to explore further the function of FAM167A expression in the lung 
epithelium and immune cells in order to investigate its potential role in triggering of 
autoimmunity.  
The transcription profiles of Fam167a and Fam167b in mice scarcely overlap. The highest 
transcription of Fam167b was detected in the adrenal gland, moderate transcription was 
observed in kidney and liver. Both the ImmGen (Figure 2) and other databases show 
specifically high transcription of Fam167b in microglial cells. According to the cancer cell line 
encyclopedia FAM167B has specifically high transcription in human melanoma cell lines. To 
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conclude, both genes show distinct expression profiles at the organ level, and both are 
transcribed in distinct immune cell subsets.  
 
4.6 Diora-1 deficient mice present with weight loss, proteinuria, increased 
IgM levels and altered B cell frequencies, with B1a cells showing 
metabolic activation 
For investigating the function of Diora-1 within the whole organism, we established a knock-
out mouse (Paper III). Diora-1 deficient mice were viable, and no embryonic lethality or 
shortened life-expectancy was observed. Further, no major malformations or 
pathohistological abnormalities were discovered. In old (26 weeks or more) male Diora-1 
deficient mice, we noted decreased body weight, increased kidney size, and elevated protein 
levels in the urine. Also, no differences in peripheral blood counts could be detected. 
However, immunoglobulin levels were altered in serum. While IgA was decreased, elevated 
levels of IgM were measured, and higher numbers of splenic IgM producing cells were 
observed. IgG levels did not differ between WT and knock-out mice. Characterizing immune 
subsets in the spleen revealed increased levels of B cells, in particular, B1a, in Diora-1 deficient 
mice compared to wild-type mice. Similarly, IgM levels were elevated Diora-1 deficient mice 
upon vaccination. Transcriptomic profiling of splenic B1a cells detects significant alterations 
in the gene signatures of oxidative phosphorylation, fatty acid metabolism, and mTorc1.  
One explanation for the decreased body weight could be that IgA deficiency in the gut has 
been linked to defects in the lipid metabolism [100]. Alternatively, the weight loss might be 
explained by the malfunctioning of the kidney, the leakage of protein into the urine or the 
ongoing inflammation in these mice.  
To understand the altered B cell frequencies in Diora-1 deficient mice, it would be highly 
relevant to investigate if extrinsic or intrinsic factors cause this dysregulation. Therefore, one 
could employ lineage-specific knock-out models. Considering that Diora-1 deficient mice 
produce elevated IgM antibodies but reduced levels of those more matured 
immunoglobulins, the first thing that comes to mind is a malfunction in the class-switch 
process. However, as normal IgG levels were observed, this would be partial or specific for 
class-switch related to generating IgA. An alternative explanation is that cells preferentially 
producing IgM are expanded in Diora-1 deficient mice. This may be explained by the 
increased B1a cell population in Diora-1 deficient mice. Moreover, future experiments may 
test, if the IgM molecules of Diora-1 deficient mice are autoreactive.  
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The transcriptomic profile we see in the B1a cells of Diora-1 deficient mice resembles the gene 
signature in metabolically activated cells. Recently, the field of immune metabolism has 
received increased attention, with the understanding that activated T and B cells shift to the 
more energy costly but faster metabolic process of glycolysis. In a lupus mouse model, the 
disease could be reversed by antagonizing glycolysis in CD4+ T cells, proving the relevance of 
immune metabolomics for developing novel therapeutic strategies for AID [101].  
Taken together, we see signs of inflammation or immune dysregulation in Diora-1 deficient 
mice. In the Diora-1 knock-out mice, we observed an increase in IgM and decrease of IgA. 
The serological pattern is also disturbed in patients with pSS compared to healthy donors. 
Specifically, they present with decreased IgM, increased IgA and very high IgG levels, 
especially of the IgG1 subtype [102]. Therefore, it might be relevant to test further if the IgG 
subclasses are disturbed in Diora-1 deficient mice. 
However, one should keep in mind that the disease-associated SNP results in increased 
DIORA-1 transcription. Thus, the increased DIORA-1 expression is assumed to contribute to 
disease pathogenesis. A Diora-1 overexpression mouse model could be implemented, 
eventually in combination with a disease model, to investigate if the gene explains some of the 
features typical for the human disease.  
 
4.7 Diora-2 deficient mice show no obvious phenotypical aberrancies, but 
their microglia show variable surface marker expression, increased IFN 
score, and an altered gene signature in cell motility pathways 
Diora-2 deficient mice were generated, and the functionality of the gene trap confirmed 
(Paper IV). The mice were viable and showed no gross malformations. We conclude, 
therefore, that the gene is not vital in development, limiting the cells expressing it or that the 
mice may compensate for its function through other regulatory mechanisms. Further, no 
differences in peripheral blood counts were detected, which goes in hand with low/non 
detected expression in the cell types assessed. However, the investigation of a panel of 92 
serum proteins found significant variations between wild-type and Diora-2 deficient mice. In 
young mice, we see upregulation of S100a4 and IL-10. High levels of these proteins in serum 
have been previously associated with AID [103, 104]. The other serum proteins, which are 
significantly upregulated in Diora-2 deficient mice, function in a wide range of processes 
including immune regulation and cell migration. In old Diora-2 deficient mice, 15 out of 92 
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serum proteins are significantly downregulated. This may reflect a secondary effect resulting 
in the dysregulation of several pathways due to the prolonged absence of Diora-2.  
Next, we characterized the myeloid immune cell populations in the brain, as we had learned 
from public databases that microglia are specifically high in Diora-2 transcription. We 
observed no changes in the cell counts, but the surface markers CD11c (ITGAX), CD11b 
(ITGAM), and CD45 (PTPRC) were elevated on the microglia of Diora-2 deficient mice. 
Taking into account that the logic for investigating DIORA-2 results from the genetic 
association of its only other gene family member DIORA-1 with rheumatic autoimmune 
diseases, it may be noteworthy that both ITGAM and ITGAX are genetically associated with 
SLE [49]. Furthermore, the risk allele of CD11b (ITGAM) correlates with increased INF-I 
levels in SLE patients [105]. Considering that Diora-2 localizes to the cytosol, we assumed 
that the increase of the surface marker expression is a secondary result of a dysregulation 
within the microglia of Diora-2 deficient mice. Therefore, we performed a microarray analysis 
to understand the transcriptional regulation in more detail. We detected many significantly 
differentially expressed genes in the microglia of Diora-2 deficient mice. In particular, the 
gene enrichment analysis points to alterations in the pathways of positive regulation of 
immune responses, leukocyte migration, cell-cell adhesion, granulocyte chemotaxis, and 
acute inflammatory response. Moreover, we deducted an elevated IFN score from the altered 
gene expression in the microglia of Diora-2 deficient mice. The elevated IFN in microglia may 
cause or result from infection, inflammation, neurodegeneration, morphologically changes in 
ramification, or production of reactive oxygen species (ROS) [106-110]. The generation of a 
conditional knock-out mouse strain that lacks Diora-2 expression specifically in microglial 
cells may tackle the questions if the observed phenotype is intrinsic to the cells or not.  
Overall, the observed phenotype is less prominent as in Diora-1 KO mice. In microglia of 
Diora-2 deficient mice, we saw alterations in surface marker expression, IFN score, and 
pathways connected to immune regulation, migration, and intercellular communication.  
 
4.8 DIORA-2 acts in proximity to MRCKA, MRCKB, and TXNL1 
To understand the molecular function of DIORA-2 we established a proximity labeling and 
identified three potential interaction partners, namely MRCKA (CDC42BPA), MRCKB 
(CDC42BPB), and TXNL1 (Paper IV, Figure 4). Many more hits were identified in each run 
(Table 1); however, these three hits were the ones shared among all three runs.  
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On the one hand, TXNL1 is a redox-active cofactor of the 26 S proteasome, widely expressed, 
and abundant in cytosol and nucleus [111]. On the other hand, MRCK kinases localize to 
acto-myosin clusters, tightly interact with CDC42, and regulate acto-myosin contractility, 
thus consequently modulate cell adhesion, motility, and endosomal trafficking [112-114]. 
Currently, no Cdc42bpa or Cdc42bpb knock-out mice are available. Hence it is pure 
speculation if they would share similar phenotypic features to our Diora-2 mice. However, the 
knock-out of the MRCK homolog Gek in drosophila results in abnormal accumulation of 
F-actin [115]. Therefore, we should check the actin localization pattern in relevant cells of our 
Diora-2 deficient mice. 
In neutrophils, Cdc42 has been suggested to regulate cell polarity and migration towards the 
site of inflammation by crosstalk between CD11b, WASp, and microtubules [116, 117]. 
Furthermore, CD11b dysregulation has been shown on neutrophils of WASp mutants and 
Cdc42 KO ([118], unpublished Keszei et al). Based on this connection between Cdc42 and 
CD11b, it is not surprising that we see altered levels of CD11b on the microglia of Diora-2 
deficient mice. Further, this explains that the gene expression of pathways responsible for 
chemotaxis, cell migration, and cell-cell adhesion was altered in microglia. In order to 
understand the impact of DIORA-2 on chemotaxis, cell motility, and polarity, it would be 
interesting if DIORA-2 knock-out or knock-down cells exhibit impairments in cell migration 
experiments. 
 
4.9 DIORA-1 and DIORA-2 differ in function but potentially share interaction 
partners  
The two knock-out models established to study the function of the Diora-1 and Diora-2 
exhibit different phenotypes, however, both show alterations in the immune system. 
Furthermore, when we identified proteins proximal to DIORA-2, this list overlapped with the 
BioPlex interaction dataset for DIORA-1 in MRCKA and MRCKB. Considering that 
DIORA-1 and DIORA-2 potentially share some interaction partners, one could speculate, if 
they have similar functions, which would go together with the high homology between both 
proteins. However, this function may be context dependent considering their distinct 
expression profiles. A double knock-out mouse model could help to understand if both genes 
complement each other or function independently.  
MRCKA and MRCKB interact with Cdc42, which modulates the cytoskeleton via WASp. In 
dendritic cells, antigen uptake has been shown to be dependent on Cdc42 [119]. When B cells 
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are specifically deprived of Cdc42 expression, these B cells exhibit a block in development, 
impaired BCR signaling, antigen presentation, T cell interaction, and fail to differentiate into 
antibody-producing cells [120, 121]. Another interesting interaction partner for MRCKA is 
Fc𝛾𝛾R1A, according to the BioPlex database. Fc𝛾𝛾Rs have been associated with several 
autoimmune diseases [122] and function both in innate as well as adaptive immune 
responses, for example, antigen presentation and phagocytosis of IgG-coated particles. To 
conclude, these cascades may explain how Diora-1 deficiency results in an altered B cell 
phenotype.  
Another member of the MRCK family, namely MRCKG, which also contributes to the 
reorganization of the cytoskeleton, is associated with chronic kidney disease [123]. 
Considering that DIORA-1 was also linked to MRCKG in the BioPlex database, this may 
relate to the kidney phenotype we observed in the knock-out model.  
Generally, kinases are promising drug targets. First MRCK inhibitors have been already 
developed and proved to affect cell motility [124]. That makes this pathway a promising 
candidate to further explore concerning its relevance in both cancer and immunity as 
potential targets for novel therapies.  
 
Figure 2: Fam167a and Fam167b transcription in murine immune cells. Data extracted from 
ImmGen database.   
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Hit Full gene name  Ratio  
CDC42BPB CDC42 binding protein kinase beta (DMPK-like) 6,64 
FAM167B family with sequence similarity 167, member B 6,64 
TXNL1 thioredoxin-like 1 6,64 
NCCRP1 non-specific cytotoxic cell receptor protein 1 homolog (zebrafish) 6,64 
CAT catalase 6,64 
TGM1 transglutaminase 1 6,64 
PKP1 plakophilin 1 6,64 
S100A11 S100 calcium binding protein A11 6,64 
TIMP3 TIMP metallopeptidase inhibitor 3 6,64 
MDK midkine (neurite growth-promoting factor 2) 6,64 
CDSN corneodesmosin 6,64 
SERPINB12 serpin peptidase inhibitor, clade B (ovalbumin), member 12 6,64 
BLMH bleomycin hydrolase 6,64 
PIP prolactin-induced protein 6,64 
MTX3 metaxin 3 6,64 
S100A14 S100 calcium binding protein A14 6,64 
XP32 Skin-specific protein 32 6,64 
TADA2B transcriptional adaptor 2B 6,64 
POF1B premature ovarian failure, 1B 6,64 
PHLPP2 PH domain and leucine rich repeat protein phosphatase 2 6,64 
ZNF829 Isoform 3 of Zinc finger protein 829 6,64 
FABP5 fatty acid binding protein 5 (psoriasis-associated) 6,64 
MOCOS molybdenum cofactor sulfurase 6,64 
SERPINA3 serpin peptidase inhibitor, clade A, member 3 6,64 
AZGP1 alpha-2-glycoprotein 1, zinc-binding 6,64 
CDC42BPA CDC42 binding protein kinase alpha (DMPK-like) 5,38 
HAL histidine ammonia-lyase 4,67 
UBFD1 ubiquitin family domain containing 1 3,27 
KIAA0319L KIAA0319-like 2,84 
FAM114A2 family with sequence similarity 114, member A2 2,55 
SBSN suprabasin 1,11 
 
Table 1: Proteins identified in SILAC BioID2-FAM167B experiment, sorted by the log2 ratio 
of abundance sample/control, filtered with crapome. Detailed description of the method can 
be found in Paper IV.  
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5 CONCLUSION AND FUTURE PERSPECTIVE 
 
Understanding the function of uncharacterized genes 
Many genes in the human genome are merely annotated with very little or nothing know 
about their function. The undertaking of elucidating the function of these numerous genes 
will require the consistent effort of many researchers. Nevertheless, this exploration is 
imperative to proceed in our understanding of the complex networks orchestrating the 
biological processes within in the cell and complex multicellular organism. It is entirely 
unforeseeable today, where future biological discoveries will lead us, presumably not only to a 
refined knowledge on the processes within organisms but potentially also to yet unpredictable 
applications.  
 
Exploring the FAM167 gene family 
Here, we demonstrate the first effort to characterize the FAM167 gene family. Our interest in 
this particular gene family originated not only from the passion for a basic understanding of 
gene function but also that combined evidence (GWAS, eQTL, present in immune cells) 
make FAM167A a strong candidate gene to contribute to the pathogenesis of rheumatic 
autoimmune disease. The first steps for characterizing FAM167A and FAM167B were taken 
both at the cellular and whole organism level. Based on our findings hitherto, we speculate 
that the genes exert their function in immune pathways and cell motility. Further 
complementing in vitro and in vivo studies will be required to deepen our understanding of 
their function.  
 
Revealing the etiology of autoimmune diseases  
We found that the FAM167A staining pattern in the salivary glands of patients with Sjögren’s 
syndrome correlates with focus score, immunoglobulin and autoantibody levels. 
Understanding how FAM167A promotes the production of auto-antibodies and infiltration 
of the target organ might shed light on factors that are involved in the pathogenesis of disease. 
The etiology of AID is complex, and many pathways are involved. However, if we further 
explore the function of FAM167 proteins in modulating immunological processes, we might 
gain insight into their contribution to disease and eventually find novel therapeutic targets.  
 30 
Suggested model of molecular function 
We detected that the DIORA proteins co-localize with vesicles and they are expressed in 
distinct immune cell subsets. Moreover, we show that the DIORA-proteins interact with the 
MRCK proteins. These are regulators of CDC42, a small GTPase vital to many cellular 
pathways. CDC42 is mainly known to control cell polarity and subsequently cell motility via 
CD11b and other proteins. This may explain our finding of increased CD11b expression and 
altered cell migration pathways in the microglia of Diora-2 deficient mice.  
Also, B cell-specific deletion of Cdc42 has strong phenotypical consequences like impairment 
in antibody production, plasma cell differentiation, and interaction with T cells. Thus, we 
speculate that our observation of IgM increase in Diora-1 deficient mice and the IgG increase 
in patients with Sjögren’s syndrome on the other side may be regulated through the same 
pathway.  
CDC42 has also been shown to regulate endocytosis, and specifically antigen presentation 
and uptake. Considering that previous reports propose DIORA-2 as a host factor in viral 
infections, this might be another mean through which the DIORA-protein exert their 
immune modulatory function.  
Besides, we also observed increased CD45 expression on Diora-2 deficient microglia. This 
and other tyrosine kinases act through Src kinases on CDC42. Therefore, it would be 
interesting to investigate whether the gene neighbors DIORA-1/BLK act in similar pathways 
or even collaborate. 
Considering the inflammatory phenotype in Diora-1 deficient mice, the altered microglia 
phenotype in Diora-2 deficient mice, and the interaction with MRCK proteins, we assume 
that DIORA proteins cause dysregulation of CDC42 resulting in defective cell migration, 
antigen processing, and antigen production.  
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Figure 3: Proposed model on molecular interactions of DIORA-1 and DIORA-2 affecting cell 
motility and other immune cell functions. 
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